ClinicalTrials.gg

TargetBeta

MS4A1

membrane spanning 4-domains A1 · also B1, Bp35, FMC7, CD20 · CD molecules

24 programs in company-led studies act on MS4A1, from 18 companies: 9 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (20 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
RituximabruleHoffmann-La Rochephase 417518 running–NCIt
ocrelizumabruleHoffmann-La Rochephase 44213 running–NCIt
obinutuzumabruleHoffmann-La Rochephase 44211 running–ChEMBL
epcoritamabruleGenmabphase 31312 runningCD3EChEMBL
glofitamabruleHoffmann-La Rochephase 3139 runningCD3EChEMBL
ublituximabruleTG Therapeuticsphase 3237 running–NCIt
mosunetuzumabruleHoffmann-La Rochephase 3147 runningCD3EChEMBL
Anti-CD20 Monoclonal Antibody MIL62ruleBeijing Mabworks Biotechphase 3107 running–NCIt
odronextamabruleRegeneron Pharmaceuticalsphase 386 runningCD3EChEMBL
TQB2825Sino Biopharmaceuticalphase 354 runningCD3Ethe company's pipeline
zuberitamabruleBioRay Pharmaceuticalphase 332 running–NCIt
rondecabtagene autoleucelruleLyell Immunopharmaphase 322 runningCD19NCIt
zamtocabtagene autoleucelruleMiltenyi Biomedicinephase 287 runningCD19, CD4, CD8ANCIt
Autologous Anti-CD19/CD20 CAR-T Cells KITE-363ruleGilead Sciencesphase 233 runningCD19NCIt
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 222 runningCD3E, CD8Aa judged reading
GSK5926371GlaxoSmithKlinephase 222 runningCD19, CD3Ethe company's pipeline
prizloncabtagene autoleucelruleAbelZetaphase 222 runningCD19NCIt
Allogeneic Anti-CD19/CD20 CAR T-cells AVC-203ruleAvenCell Therapeuticsphase 211 runningCD19NCIt
CT204V-CD19 × CD20ruleAstraZenecaphase 211 runningCD19the studies' text
REGN9220ruleRegeneron Pharmaceuticalsphase 211 runningCD22, CD3Ethe studies' text
Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543ruleJohnson & Johnsonphase 133 runningCD3ENCIt
Anti-CD20 Bispecific Antibody DR-0201Sanofiphase 132 running–the company's pipeline
prulacabtagene leucelruleAdicet Therapeuticsphase 122 running–NCIt
HB2198ruleHinge Biophase 111 runningCD19the studies' text

Also acted on by the same programs

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.